A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

• Main Authors: Mariane Teodoro Fernandes, Jacob J Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro del Giglio, Pedro Nazareth Aguiar Jr
• Format: Article
• Language: English
• Published: BioExcel Publishing Ltd 2018-11-01
• Series: Drugs in Context
• Subjects: breast cancer; targeted therapy; endocrine therapy; cyclin-dependent kinase 4; cyclin-dependent kinase 6
• Online Access: https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors
• ISSN: 1740-4398; 1740-4398

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.